PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

BACKGROUND: The purpose of this phase Ib clinical trial was to determine the maximum tolerated dose (MTD) of PR-104 a bioreductive pre-prodrug given in combination with gemcitabine or docetaxel in patients with advanced solid tumours. METHODS: PR-104 was administered as a one-hour intravenous infusi...

Descripción completa

Detalles Bibliográficos
Autores principales: McKeage, Mark J, Jameson, Michael B, Ramanathan, Ramesh K, Rajendran, Joseph, Gu, Yongchuan, Wilson, William R, Melink, Teresa J, Tchekmedyian, N Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495895/
https://www.ncbi.nlm.nih.gov/pubmed/23098625
http://dx.doi.org/10.1186/1471-2407-12-496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495895/
https://www.ncbi.nlm.nih.gov/pubmed/23098625
http://dx.doi.org/10.1186/1471-2407-12-496

Ejemplares similares